Citigroup
INMB icon

Citigroup’s INmune Bio INMB Stock Holding History

Citigroup’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160 Sell
98
-1,374
-93% -$1.9K ﹤0.01% 5502
2026
Q1 		$1.66K Sell
1,472
-331
-18% -$472 ﹤0.01% 5442
2025
Q4 		$2.81K Buy
1,803
+918
+104% +$1.64K ﹤0.01% 5398
2025
Q3 		$1.83K Sell
885
-6,021
-87% -$13.8K ﹤0.01% 5506
2025
Q2 		$16K Sell
6,906
-3,214
-32% -$23.6K ﹤0.01% 5124
2025
Q1 		$79K Sell
10,120
-711
-7% -$5.65K ﹤0.01% 4720
2024
Q4 		$50.6K Buy
10,831
+1,074
+11% +$5.6K ﹤0.01% 5083
2024
Q3 		$52.6K Buy
9,757
+7,101
+267% +$50.5K ﹤0.01% 5009
2024
Q2 		$23.4K Sell
2,656
-45,388
-94% -$447K ﹤0.01% 4955
2024
Q1 		$565K Buy
48,044
+12,144
+34% +$147K ﹤0.01% 3483
2023
Q4 		$404K Buy
+35,900
New +$301K ﹤0.01% 3561
2022
Q3 		– Sell
-1,300
Closed -$11K – 6068
2022
Q2 		$11K Buy
+1,300
New +$9.67K ﹤0.01% 5325
2021
Q2 		– Sell
-1,908
Closed -$23K – 6254
2021
Q1 		$23K Buy
+1,908
New +$34.3K ﹤0.01% 5167

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's INMB Position: Q2 2026 in Review

Citigroup reduced its INmune Bio (INMB) stake by 93% in Q2 2026, selling an estimated $1.9K and leaving 98 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #5502.

Citigroup first reported a position in INMB in Q1 2021 and has held it in 13 quarters since. The position peaked at $565K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Citigroup held 98 shares of INmune Bio worth $160 as of Q2 2026.
  • Citigroup sold 1,374 INmune Bio shares in Q2 2026, an estimated $1.9K.
  • INmune Bio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5502 holding.
  • Citigroup first reported a position in INmune Bio in Q1 2021 and has held it in 13 quarters since.
  • Citigroup's INmune Bio position peaked at $565K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.